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angiography (DSA) when used to diagnose peripheral arterial occlusive disease 
(PAOD) from a German Hospital’s perspective. METHODS: In this study we consid-
ered the direct cost attributable to the radiological department in a hospital, including 
proportionate investigation costs such as personnel and machine usage. The costs for 
contrast agents and consumer goods were considered in a second step as they vary 
strongly from hospital to hospital. A total of eleven examinations, each of MRA and 
DSA type, were documented and analyzed. RESULTS: The investigation costs for a 
MRA examination excluding consumer goods was found to be a142.38 and about 
20% (a34.25) lower than that of a DSA-examination (a176.63), owing to the shorter 
occupation time of the operating room with MRA (average: 32 minutes) than with 
DSA (average: 58 minutes) and resulting in a lower proportional investigation costs 
for machine, room, and personnel per examination assuming routine operating hours 
of 12 hours per day at seven days a week. When the list prices for consumer goods 
were also regarded, there was still an advantage for MRA of a11.22 (^7%) per 
examination. CONCLUSIONS: For patients with suspected PAOD angiography with 
contrast-enhanced MRA was found to be less costly than DSA. Our results align with 
cost-effectiveness analyses conducted in the UK and the USA that included in addition 
the outcomes of diagnosis-based therapeutic decisions. Increased use of contrast-
enhanced MRA for diagnostic purposes and optimization of cost drivers might 
promote cost reductions in radiological departments in German hospitals.
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OBJECTIVES: To determine the health care cost and the labour incapacity of hyper-
tension (AHT) according to different levels of morbidity in primary care setting 
(PC). METHODS: Retrospective-multicentric design. Patients’ q 40 year from seven    
teams of PC (year 2008) were included. Main measures: age, sex, cardiovascular co-
morbidity, Charlson index and general morbidity levels (Adjusted Clinical Groups; 
low, moderate and high). It was established a model of direct costs (differentiating: 
ﬁxed and variable [drugs, tests and referrals]) and indirect. Logistic regression analysis 
and ANCOVA was used for the model correction. Statistical signiﬁcance: P  0.05 
RESULTS: The prevalence of hypertension was 28.4% (95% conﬁdence interval [CI]: 
27.4–29.4%), mean age 67.5 (11.7) years and 56.7% of female. 73.2% of patients 
had moderate co-morbidity (95% CI: 71.3–75.1%). The average/unit of the total cost 
was a1312.1 (range, low co-morbidity: a633.1, moderately: a1297.2 and high: 
a2307.8, P  0.001). Health care cost represented 98.2% of the whole and medication           
69.4%. Morbidity with high cardiovascular event (OR  3.5), smoking (OR  1.4) 
and obesity (OR  1.3), P  0.02 was associated. The correlation of the health cost 
and total cost with the episodes number was 51.4% and 50.6% respectively, P  
0.001. CONCLUSIONS: Patients with AHT have a high health care cost, mainly in 
pharmacy. The total costs increase with age and level of general morbidity. The AHT 
should be considered in conjunction with other cardiovascular risk factors. The cost 
in work labour incapacity is low.
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OBJECTIVES: To assess direct in-hospital costs of CABG in patients hospitalized with 
acute heart failure (AHF) from health care payer perspective and to analyze the burden 
of CABG procedure in total in-hospital cost of AHF. METHODS: From total 1357 
patients hospitalized with AHF in University Hospital Brno (UH) between 2005 and 
2007, 4.6% patients were sent to undergo CABG procedure at the Cardio-surgical 
Centre. Direct cost (include ﬂat rate of admission, stay, medication and service) associ-
ated with contiguous AHF hospitalisation and cost of consecutive CABG were evalu-
ated together as well as separately. (1a  28.63CZK). RESULTS: Forty-six patients  
with de-novo AHF and 17 patients with acute decompensation of chronic heart failure 
were analysed (79.4% male; mean age 68.3 years; 38.7% after myocardial infarction). 
The median length-of-stay (LOS) in both centres was 25 days, mean cost a11953. 
Both LOS (median 23.5; 23.5 and 31 days) and costs (mean a 8855; a10,915; a16,742) 
increased over the years 2005–2007 (statistical signiﬁcant difference in in-hospital 
costs p  0.006, Kruskal-Wallis test). 5 patients stayed in intensive care unit (ICU) 
with median LOS 20 days and mean cost a25,928, others spent median 10 days in 
ICU and 16 days in standard cardiology unit with mean cost a10748. Stay in UH 
Brno formed 9.2% total costs (median LOS 11 days; mean a1,098; PCI performed in 
7.9% patients); the remainder was concerned with CABG procedure (mean a10,855; 
LOS 15 days). Two patients (3.2%) died after CABG. CONCLUSIONS: Acute heart 
failure is a life threatening disease which includes variable causes and complications. 
One of the most costly procedures in AHF patients is revascularisation by means of 
percutaneous coronary intervention or CABG. CABG made 15.3% of total in-hospital 
costs although it was carried out in less than 5% patients.
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OBJECTIVES: Hyponatremia has been associated with risks of in-hospital complica-
tions and mortality in patients with heart failure (HF). However, the nature of the 
relationship between serum sodium (Na) and length of stay in the setting of contem-
porary HF treatment strategies is not known. We evaluated the impact of hyponatre-
mia on LOS from the multinational EVEREST (Efﬁcacy of Vasopressin Antagonism    
in Heart Failure: Outcome Study with Tolvaptan) trial in patients hospitalized with 
HF. METHODS: In the standard of care (SOC) arm of EVEREST, initial LOS 
of normonatremic patients (q135 mEq/L) was compared to hyponatremic patients 
(135 mEq/L, 130 mEq/L, respectively) to assess the association between Na and 
overall LOS. Bivariate analysis was performed producing unadjusted mean LOS dif-
ferences between normatremic and hyponatremic patient cohorts. An analysis of 
covariance (ANCOVA) model was employed to account for potential regional varia-
tion in care delivery. The model was adjusted for hyponatremia status as a factor 
and both region and hyponatremia status and region interaction as covariates. 
Signiﬁcance was assessed with student’s t-test at (p  0.05). RESULTS: Patients with 
admission Na  135 mEq/L (N  216) had an adjusted LOS 3.06 (SE  .533) days 
longer than patients Na q 135 mEq/L (N    1798)(p  0.001). More severely hypona-
tremic patients (130 mEq/L)(N  48) had an adjusted LOS 4.91 (SE  1.16) days 
longer than those with an admission Na q 135 mEq/L (N    1957)(p  0.001). The 
magnitude and direction of the association between hyponatremia and LOS was con-
sistent in both the bivariate and multivariate analyses. These ﬁndings were also con-
ﬁrmed in the limited subset of U.S. patients: hyponatremia (n  68)(135 mEq/L) was 
associated with a LOS 1.39 days longer than normonatremia (n  489)(q135 mEq/L) 
(p  0.05). CONCLUSIONS: Hyponatremia in patients hospitalized for heart failure 
is associated with a statistically signiﬁcant longer LOS as compared with normona-
tremic patients. Further evaluation of the economic burden of this comorbidity is 
warranted.
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OBJECTIVES: Readmission within 30 days of discharge following an acute myocar-
dial infarction (AMI) has been adopted as a quality indicator for US hospitals. 
Whether speciﬁc therapeutic interventions lead to reductions in readmissions is 
unknown. METHODS: We compared rates of readmission within 30 days, and associ-
ated hospitalization costs in patients who were originally admitted for acute coronary 
syndromes (ACS) with planned PCI, and treated with prasugrel vs. clopidogrel in 
the TRITON-TIMI 38 Trial. Patients with a history of stroke/TIA were excluded. 
Data for rehospitalizations were collected for patients from 8 pre-speciﬁed countries 
(U.S.,Australia,Canada,Germany,Italy,Spain,UK,France; n  3233 prasugrel, n  3215 
clopidogrel). Diagnosis Related Groups (DRGs) were used to classify type of hospi-
talization, to which average 2005 Medicare reimbursement rates were applied. Rehos-
pitalization rates were compared between groups using Poisson regression. RESULTS: 
There was a reduction in the 30-day rate of rehospitalization for revascularization 
(PCI or CABG) with prasugrel vs. clopidogrel (4.33 vs. 5.69 per 100 patients, p  
0.015) as well as for PCI (3.80 vs. 4.95 per 100 patients, p  0.03). The reduction in 
PCI rehospitalizations was primarily among patients with both PCI and AMI (0.31 
vs. 1.06, p  0.0006). For patients with an index ST-elevation MI, there was a signiﬁ-
cant reduction in PCI rehospitalizations in the setting of an MI (0.28 vs. 1.46, p  
0.034). The overall 30-day rehospitalization rate did not differ signiﬁcantly (9.6 pra-
sugrel vs. 10.8 clopidogrel, per 100 patients, p  0.14) though total 30-day rehospi-
talization costs were lower for prasugrel ($1145 vs. $1419; difference  $274, 95% 
CI: $525, $28). The difference in costs due to PCI-related rehospitalizations was 
$214 ($387,49). CONCLUSIONS: For ACS patients with no history of stroke/TIA 
and planned PCI, treatment with prasugrel vs. clopidogrel is associated with a lower 
rate of rehospitalization for revascularization–primarily PCI in the setting of MI, and 
concomitant cost savings. These results may be useful in establishing patient manage-
ment strategies in the current quality and reimbursement environment.
